<div id="readability-page-1">11:58 AM EDT, 05/15/2026 (MT Newswires) -- Danaher ( DHR ) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher ( DHR ) to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.Danaher ( DHR ) is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.RBC Capital Markets resumed coverage on Danaher ( DHR ), with an outperform rating and a $200 price target.Shares of Danaher ( DHR ) were down 1.1% in Friday afternoon trading.Price: 162.75, Change: -1.79, Percent Change: -1.09 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

LABU

RBC Capital Markets projects Danaher (DHR) could achieve 6% revenue growth in 2027, driven by a rebound in bioprocess demand and improving markets. The firm notes strong demand for bioprocess consumables and equipment. Danaher is also addressing gaps in its Beckman Coulter business and expects growth from its Masimo acquisition. RBC resumed coverage with an outperform rating and a $200 price target, despite a 1.1% drop in shares to $162.75.

fidelity

Danaher

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health Equip

VanEck Biotech ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Direxion S&P Biotech Bull 3X

ROYAL BANK OF CANADA

Masimo

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says